Zocilurtatug Pelitecan clinical trials
Also written ZL-1310.
How each study uses Zocilurtatug Pelitecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Zocilurtatug Pelitecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ZL-1310
- 5
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Zai Lab (Shanghai) Co., Ltd. (3) · Boehringer Ingelheim (1) · Amgen (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Zocilurtatug Pelitecan.
- May 2027A Study of ZL-1310 in Subjects With Small Cell Lung CancerPhase 1 · Zai Lab (Shanghai) Co., Ltd.
- Aug 2027A Study of ZL-1310 in Participants With Selected Solid TumorsPhase 1/2 · Zai Lab (Shanghai) Co., Ltd.
Studies
Open first, then newest update. How each study uses Zocilurtatug Pelitecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersRecruitingPhase 1/2Boehringer IngelheimNCT07707895Written as ZL-1310
- A Study of ZL-1310 in Subjects With Small Cell Lung CancerRecruitingPhase 1Zai Lab (Shanghai) Co., Ltd.NCT06179069Written as ZL-1310
- A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)RecruitingPhase 3Zai Lab (Shanghai) Co., Ltd.NCT07218146Written as ZL-1310
- A Study of ZL-1310 in Participants With Selected Solid TumorsRecruitingPhase 1/2Zai Lab (Shanghai) Co., Ltd.NCT06885281Written as ZL-1310
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingPhase 1AmgenNCT07531095Written as ZL-1310
What changed recently
From the registry's own updates since Oct 18, 2026.